Skip to main content
SpringerLink
Log in

Prostate Gland

  • Chapter
  • First Online:
Handbook of Practical Immunohistochemistry

  • 1896 Accesses

Abstract

This chapter provides a practical overview of frequently used markers in the diagnosis and differential diagnosis of both common and rare neoplasms of prostate gland, with a specific focus on adenocarcinoma and its mimickers. The chapter contains 41 questions; each question is addressed with a table, concise note, and representative pictures if applicable. In addition to the literature review, the authors have included their own experience and tested numerous antibodies reported in the literature. The new immunomarkers, such as ERG and NKX3.1, are discussed and illustrated. The most effective diagnostic panels of antibodies have been recommended for many entities, such as CK7, PAX2, and MUC6 being suggested as the best diagnostic panel for distinguishing seminal vesicles from prostatic ductal adenocarcinoma and high-grade prostatic intraepithelial neoplasia. Furthermore, immunophenotypes of normal prostate and seminal vesicles have been described, which tends to be neglected in literature.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classifications of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2016.

    Google Scholar 

  2. Epstein JI. Diagnosis of limited adenocarcinoma of the prostate. Histopathology. 2012;60(1):28–40.

    Article  PubMed  Google Scholar 

  3. Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications. 3rd ed. Philadelphia: Saunders Elsevier; 2010.

    Google Scholar 

  4. Liu H, Lin F, Zhai Q. Prostate gland. In: Lin F, Prichard JW, Liu H, Wilkerson M, Schuerch C, editors. Handbook of practical immunohistochemistry: frequently asked questions. New York: Springer; 2015. p. 397–420.

    Google Scholar 

  5. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008;132(9):1388–96.

    Article  PubMed  Google Scholar 

  6. Hammerich KH, Ayala GE, Wheeler TM. Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). Arch Pathol Lab Med. 2008;132(3):432–40.

    Article  PubMed  Google Scholar 

  7. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22(1):88–104.

    Article  PubMed  Google Scholar 

  8. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  9. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol. 1994;102(4 Suppl 1):S31–7.

    CAS  PubMed  Google Scholar 

  10. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–61.

    Article  CAS  PubMed  Google Scholar 

  11. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology. 2001;57(6):1179–83.

    Article  CAS  PubMed  Google Scholar 

  12. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.

    Article  CAS  PubMed  Google Scholar 

  13. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.

    CAS  PubMed  Google Scholar 

  14. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30(4):628–36.

    Article  PubMed  Google Scholar 

  15. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83(11):2259–69.

    Article  CAS  PubMed  Google Scholar 

  16. Chang SS. Monoclonal antibodies and prostate-specific membrane antigen. Curr Opin Investig Drugs. 2004;5(6):611–5.

    CAS  PubMed  Google Scholar 

  17. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50(4):472–83.

    Article  CAS  PubMed  Google Scholar 

  18. Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW, et al. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol. 2006;30(10):1231–6.

    Article  PubMed  Google Scholar 

  19. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. Anticancer Res. 1997;17(3C):2343–6.

    CAS  PubMed  Google Scholar 

  20. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. Anticancer Res. 1997;17(4A):2577–81.

    CAS  PubMed  Google Scholar 

  21. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer. 1998;78(3):360–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol. 1996;106(2):242–7.

    Article  CAS  PubMed  Google Scholar 

  23. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118(2):202–7.

    Article  CAS  PubMed  Google Scholar 

  24. Carder PJ, Speirs V, Ramsdale J, Lansdown MR. Expression of prostate specific antigen in male breast cancer. J Clin Pathol. 2005;58(1):69–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cheng CW, Chan LW, Ng CF, Chan CK, Tse MK, Lai MM. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen. Int J Urol. 2006;13(4):463–5.

    Article  PubMed  Google Scholar 

  26. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24(4):579–86.

    Article  CAS  PubMed  Google Scholar 

  27. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117(3):471–7.

    Article  PubMed  Google Scholar 

  28. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001;61(4):1563–8.

    CAS  PubMed  Google Scholar 

  29. Kalos M, Askaa J, Hylander BL, Repasky EA, Cai F, Vedvick T, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004;60(3):246–56.

    Article  CAS  PubMed  Google Scholar 

  30. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31(9):1351–5.

    Article  PubMed  Google Scholar 

  31. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol. 2007;2:41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35(3):432–41.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13(3):228–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Liu H, Shi J, Wilkerson M, Yang XJ, Lin F. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. Ann Clin Lab Sci. 2013;43(1):3–9.

    CAS  PubMed  Google Scholar 

  35. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35(7):1014–20.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35(7):1062–8.

    Article  PubMed  Google Scholar 

  37. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”. Am J Surg Pathol. 2011;35(4):608–14.

    Article  PubMed  Google Scholar 

  38. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23(8):1061–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31(8):1246–55.

    Article  PubMed  Google Scholar 

  40. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097–105.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate. 2003;55(2):111–7.

    Article  CAS  PubMed  Google Scholar 

  42. Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol. 2001;165(4):1329–34.

    Article  CAS  PubMed  Google Scholar 

  43. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60(6):1677–82.

    CAS  PubMed  Google Scholar 

  44. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27(6):772–8.

    Article  PubMed  Google Scholar 

  45. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol. 2004;122(2):275–89.

    Article  CAS  PubMed  Google Scholar 

  46. Yang XJ, Laven B, Tretiakova M, Blute RD Jr, Woda BA, Steinberg GD, et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology. 2003;62(2):282–6.

    Article  PubMed  Google Scholar 

  47. Amin M, Beach R, Gown AM, Yaziji H, Malhotra R, Amin MB. Use of a novel immunohistochemical (IHC) panel (P504S, p63 and 34betaE12) in the diagnosis of post-radiation therapy (PRT) prostate cancer (PCa) [abstract]. Mod Pathol. 2003;16:139A.

    Google Scholar 

  48. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29(7):874–80.

    Article  PubMed  Google Scholar 

  49. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157(6):1769–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Baydar DE, Kulac I, Gurel B, De Marzo A. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis. Int J Surg Pathol. 2011;19(1):131–6.

    Article  PubMed  Google Scholar 

  51. Giannico GA, Ross HM, Lotan T, Epstein JI. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study. Am J Surg Pathol. 2013;37(9):1401–6.

    Article  PubMed  Google Scholar 

  52. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol. 2008;32(12):1890–5.

    Article  PubMed  Google Scholar 

  53. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002;26(9):1151–60.

    Article  PubMed  Google Scholar 

  54. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI. Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology. 1995;45(6):981–6.

    Article  CAS  PubMed  Google Scholar 

  55. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15(12):1302–8.

    Article  PubMed  Google Scholar 

  56. Gupta RK. Immunoreactivity of prostate-specific antigen in male breast carcinomas: two examples of a diagnostic pitfall in discriminating a primary breast cancer from metastatic prostate carcinoma. Diagn Cytopathol. 1999;21(3):167–9.

    Article  CAS  PubMed  Google Scholar 

  57. Holmes GF, Eisele DW, Rosenthal D, Westra WH. PSA immunoreactivity in a parotid oncocytoma: a diagnostic pitfall in discriminating primary parotid neoplasms from metastatic prostate cancer. Diagn Cytopathol. 1998;19(3):221–5.

    Article  CAS  PubMed  Google Scholar 

  58. van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol. 1993;17(4):410–4.

    Article  PubMed  Google Scholar 

  59. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol. 2008;32(9):1322–6.

    Article  PubMed  Google Scholar 

  60. Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol. 2007;31(9):1323–9.

    Article  PubMed  Google Scholar 

  61. Curtis MW, Evans AJ, Srigley JR. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity. Mod Pathol. 2005;18(4):585–90.

    Article  PubMed  Google Scholar 

  62. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol. 2009;33(5):659–68.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28(5):651–7.

    Article  PubMed  Google Scholar 

  64. Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol. 2006;30(10):1316–21.

    Article  PubMed  Google Scholar 

  65. Parwani AV, Herawi M, Epstein JI. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol. 2006;30(10):1254–9.

    Article  PubMed  Google Scholar 

  66. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65–71.

    Article  PubMed  Google Scholar 

  67. Simon RA, di Sant’Agnese PA, Huang LS, Huang LS, Xu H, Yao JL, et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009;40(2):252–8.

    Article  CAS  PubMed  Google Scholar 

  68. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol. 1992;147(3 Pt 2):804–7.

    Article  CAS  PubMed  Google Scholar 

  69. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13(3):238–42.

    Article  CAS  PubMed  Google Scholar 

  70. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24(9):1217–23.

    Article  CAS  PubMed  Google Scholar 

  71. Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125(2):228–31.

    Article  CAS  PubMed  Google Scholar 

  72. Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997;21(2):226–34.

    Article  CAS  PubMed  Google Scholar 

  73. di Sant’Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 1992;70(1 Suppl):254–68.

    Article  PubMed  Google Scholar 

  74. di Sant’Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol. 1992;23(3):287–96.

    Article  PubMed  Google Scholar 

  75. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2008;8:21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30(6):705–12.

    Article  PubMed  Google Scholar 

  77. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696–708.

    Article  CAS  PubMed  Google Scholar 

  78. McKenney JK, Amin MB, Srigley JR, Jimenez RE, Ro JY, Grignon DJ, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol. 2004;28(10):1289–98.

    Article  PubMed  Google Scholar 

  79. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum Pathol. 1998;29(12):1447–50.

    Article  CAS  PubMed  Google Scholar 

  80. Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2007;31(5):697–705.

    Article  PubMed  Google Scholar 

  81. Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M. Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med. 2007;131(4):637–40.

    Article  PubMed  Google Scholar 

  82. Iczkowski KA, Ferguson KL, Grier DD, Hossain D, Banerjee SS, McNeal JE, et al. Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am J Surg Pathol. 2003;27(12):1523–9.

    Article  PubMed  Google Scholar 

  83. Montironi R, Mazzucchelli R, Stramazzotti D, Scarpelli M, Lopez Beltran A, Bostwick DG. Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. J Clin Pathol. 2005;58(3):290–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58(4):619–24.

    Article  CAS  PubMed  Google Scholar 

  85. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008;32(3):461–7.

    Article  PubMed  Google Scholar 

  86. Torbenson M, Dhir R, Nangia A, Becich MJ, Kapadia SB. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol. 1998;11(6):552–9.

    CAS  PubMed  Google Scholar 

  87. Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol. 2009;22(10):1273–9.

    Article  CAS  PubMed  Google Scholar 

  88. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol. 2007;31(6):889–94.

    Article  PubMed  Google Scholar 

  89. Zaloudek C, Williams JW, Kempson RL. “Endometrial” adenocarcinoma of the prostate: a distinctive tumor of probable prostatic duct origin. Cancer. 1976;37(5):2255–62.

    Article  CAS  PubMed  Google Scholar 

  90. Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer. 1991;67(8):2118–24.

    Article  CAS  PubMed  Google Scholar 

  91. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol. 1999;23(7):781–5.

    Article  CAS  PubMed  Google Scholar 

  92. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer. 1986;57(1):111–9.

    Article  CAS  PubMed  Google Scholar 

  93. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004;35(10):1272–8.

    Article  CAS  PubMed  Google Scholar 

  94. Hosler GA, Epstein JI. Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Hum Pathol. 2005;36(5):480–5.

    Article  PubMed  Google Scholar 

  95. Yang XJ, Tretiakova MS, Sengupta E, Gong C, Jiang Z. Florid basal cell hyperplasia of the prostate: a histological, ultrastructural, and immunohistochemical analysis. Hum Pathol. 2003;34(5):462–70.

    Article  PubMed  Google Scholar 

  96. Rioux-Leclercq NC, Epstein JI. Unusual morphologic patterns of basal cell hyperplasia of the prostate. Am J Surg Pathol. 2002;26(2):237–43.

    Article  PubMed  Google Scholar 

  97. Zhou M, Magi-Galluzzi C, Epstein JI. Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. Anal Quant Cytol Histol. 2006;28(3):125–9.

    PubMed  Google Scholar 

  98. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol. 2003;163(3):923–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994;91(24):11733–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987;47(1):281–6.

    CAS  PubMed  Google Scholar 

  101. Thorson P, Swanson PE, Vollmer RT, Humphrey PA. Basal cell hyperplasia in the peripheral zone of the prostate. Mod Pathol. 2003;16(6):598–606.

    Article  PubMed  Google Scholar 

  102. Grignon DJ, Ro JY, Ordonez NG, Ayala AG, Cleary KR. Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: an immunohistochemical study. Hum Pathol. 1988;19(12):1425–33.

    Article  CAS  PubMed  Google Scholar 

  103. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25(11):1397–404.

    Article  CAS  PubMed  Google Scholar 

  104. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220–6.

    CAS  PubMed  Google Scholar 

  105. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287(13):1662–70.

    Article  CAS  PubMed  Google Scholar 

  106. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926–31.

    Article  PubMed  Google Scholar 

  107. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588–96.

    Article  CAS  PubMed  Google Scholar 

  108. Evans AJ. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol. 2003;56(12):892–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol. 2004;17(3):328–48.

    Article  PubMed  Google Scholar 

  110. Abrahams NA, Bostwick DG, Ormsby AH, Qian J, Brainard JA. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6. Am J Clin Pathol. 2003;120(3):368–76.

    Article  PubMed  Google Scholar 

  111. Quick CM, Gokden N, Sangoi AR, Brooks JD, McKenney JK. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis. Hum Pathol. 2010;41(8):1145–9.

    Article  CAS  PubMed  Google Scholar 

  112. Leroy X, Ballereau C, Villers A, Saint F, Aubert S, Gosselin B, et al. MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma. Am J Surg Pathol. 2003;27(4):519–21.

    Article  PubMed  Google Scholar 

  113. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41(1):35–41.

    Article  CAS  PubMed  Google Scholar 

  114. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26(9):1161–8.

    Article  PubMed  Google Scholar 

  115. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443(2):122–32.

    Article  CAS  PubMed  Google Scholar 

  116. Wu HH, Lapkus O, Corbin M. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl Immunohistochem Mol Morphol. 2004;12(4):285–9.

    Article  CAS  PubMed  Google Scholar 

  117. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004;122(4):517–23.

    Article  PubMed  Google Scholar 

  118. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29(5):579–87.

    Article  PubMed  Google Scholar 

  119. Zhou M, Magi-Galluzi C. Prostatic adenocarcinoma, prostatic intraepithelial neoplasia, and intraductal carcinoma. Surg Pathol Clin. 2008;1(1):43–75.

    Article  PubMed  Google Scholar 

  120. Novis DA, Zarbo RJ, Valenstein PA. Diagnostic uncertainty expressed in prostate needle biopsies. A College of American Pathologists Q-probes study of 15,753 prostate needle biopsies in 332 institutions. Arch Pathol Lab Med. 1999;123(8):687–92.

    Article  CAS  PubMed  Google Scholar 

  121. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol. 1995;19(3):251–60.

    Article  CAS  PubMed  Google Scholar 

  122. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer. 1987;59(4):788–94.

    Article  CAS  PubMed  Google Scholar 

  123. McNeal JE, Villers A, Redwine EA, Freiha FS, Stamey TA. Microcarcinoma in the prostate: its association with duct-acinar dysplasia. Hum Pathol. 1991;22(7):644–52.

    Article  CAS  PubMed  Google Scholar 

  124. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol. 2001;25(8):1079–85.

    Article  CAS  PubMed  Google Scholar 

  125. Nagle RB, Brawer MK, Kittelson J, Clark V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol. 1991;138(1):119–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. McNeal JE, Leav I, Alroy J, Skutelsky E. Differential lectin staining of central and peripheral zones of the prostate and alterations in dysplasia. Am J Clin Pathol. 1988;89(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  127. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol. 1997;10(11):1113–9.

    CAS  PubMed  Google Scholar 

  128. McNeal JE, Alroy J, Leav I, Redwine EA, Freiha FS, Stamey TA. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol. 1988;90(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  129. Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol. 1998;11(3):247–52.

    CAS  PubMed  Google Scholar 

  130. Tamboli P, Amin MB, Schultz DS, Linden MD, Kubus J. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Mod Pathol. 1996;9(10):1015–9.

    CAS  PubMed  Google Scholar 

  131. Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol. 2004;35(3):290–7.

    Article  CAS  PubMed  Google Scholar 

  132. Zhang PJ, Driscoll DL, Lee HK, Nolan C, Velagapudi SR. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Hum Pathol. 1999;30(2):168–72.

    Article  CAS  PubMed  Google Scholar 

  133. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003;27(3):365–71.

    Article  PubMed  Google Scholar 

  134. Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol. 2008;32(7):1060–7.

    Article  PubMed  Google Scholar 

  135. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19(12):1528–35.

    Article  PubMed  Google Scholar 

  136. Shah RB, Magi-Galluzzi C, Han B, Zhou M. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol. 2010;34(4):470–7.

    Article  PubMed  Google Scholar 

  137. Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, et al. ETS gene aberrations in atypical cribriform lesions of the prostate: implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010;34(4):478–85.

    Article  PubMed  Google Scholar 

  138. Hameed O, Humphrey PA. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2006;19(7):899–906.

    Article  PubMed  Google Scholar 

  139. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol. 1985;9(8):595–609.

    Article  CAS  PubMed  Google Scholar 

  140. Ro JY, Ayala AG, Wishnow KI, Ordonez NG. Prostatic duct adenocarcinoma with endometrioid features: immunohistochemical and electron microscopic study. Semin Diagn Pathol. 1988;5(3):301–11.

    CAS  PubMed  Google Scholar 

  141. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology. 1996;29(1):11–9.

    Article  CAS  PubMed  Google Scholar 

  142. Samaratunga H, Delahunt B. Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol. 2008;30(4):237–46.

    PubMed  Google Scholar 

  143. Epstein JI, Lieberman PH. Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol. 1985;9(4):299–308.

    Article  CAS  PubMed  Google Scholar 

  144. Tran KP, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol. 1996;20(11):1346–50.

    Article  CAS  PubMed  Google Scholar 

  145. Ro JY, Grignon DJ, Ayala AG, Fernandez PL, Ordonez NG, Wishnow KI. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol. 1990;21(6):593–600.

    Article  CAS  PubMed  Google Scholar 

  146. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;32(3):468–72.

    Article  PubMed  Google Scholar 

  147. Matsuoka Y, Arai G, Ishimaru H, Takagi K, Ito Y. Primary signet-ring cell carcinoma of the prostate. Can J Urol. 2007;14(6):3764–6.

    PubMed  Google Scholar 

  148. Ro JY, el-Naggar A, Ayala AG, Mody DR, Ordonez NG. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol. 1988;12(6):453–60.

    Article  CAS  PubMed  Google Scholar 

  149. Skodras G, Wang J, Kragel PJ. Primary prostatic signet-ring cell carcinoma. Urology. 1993;42(3):338–42.

    Article  CAS  PubMed  Google Scholar 

  150. Alline KM, Cohen MB. Signet-ring cell carcinoma of the prostate. Arch Pathol Lab Med. 1992;116(1):99–102.

    CAS  PubMed  Google Scholar 

  151. Remmele W, Weber A, Harding P. Primary signet-ring cell carcinoma of the prostate. Hum Pathol. 1988;19(4):478–80.

    Article  CAS  PubMed  Google Scholar 

  152. Kuroda N, Yamasaki I, Nakayama H, Tamura K, Yamamoto Y, Miyazaki E, et al. Prostatic signet-ring cell carcinoma: case report and literature review. Pathol Int. 1999;49(5):457–61.

    Article  CAS  PubMed  Google Scholar 

  153. Hayashi H, Kitamura H, Nakatani Y, Inayama Y, Ito T, Kitamura H. Primary signet-ring cell carcinoma of the lung: histochemical and immunohistochemical characterization. Hum Pathol. 1999;30(4):378–83.

    Article  CAS  PubMed  Google Scholar 

  154. Hejka AG, England DM. Signet ring cell carcinoma of prostate. Immunohistochemical and ultrastructural study of a case. Urology. 1989;34(3):155–8.

    Article  CAS  PubMed  Google Scholar 

  155. Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: review of 88 cases. Urology. 1999;54(1):141–4.

    Article  CAS  PubMed  Google Scholar 

  156. Fujita K, Sugao H, Gotoh T, Yokomizo S, Itoh Y. Primary signet ring cell carcinoma of the prostate: report and review of 42 cases. Int J Urol. 2004;11(3):178–81.

    Article  PubMed  Google Scholar 

  157. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol. 1997;10(6):612–29.

    CAS  PubMed  Google Scholar 

  158. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer. 1984;53(11):2478–80.

    Article  CAS  PubMed  Google Scholar 

  159. Ro JY, Tetu B, Ayala AG, Ordonez NG. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987;59(5):977–82.

    Article  CAS  PubMed  Google Scholar 

  160. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987;59(10):1803–9.

    Article  CAS  PubMed  Google Scholar 

  161. Kallakury BV, Yang F, `ge J, Smith KE, Kausik SJ, Tacy NJ, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer. 1996;78(7):1461–9.

    Article  CAS  PubMed  Google Scholar 

  162. Hagood PG, Johnson FE, Bedrossian CW, Silverberg AB. Small cell carcinoma of the prostate. Cancer. 1991;67(4):1046–50.

    Article  CAS  PubMed  Google Scholar 

  163. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol. 2004;17(3):316–27.

    Article  PubMed  Google Scholar 

  164. Miller VA, Reuter V, Scher HI. Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. Urology. 1995;46(1):111–3.

    Article  CAS  PubMed  Google Scholar 

  165. Nabi G, Ansari MS, Singh I, Sharma MC, Dogra PN. Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature. Urol Int. 2001;66(4):216–9.

    Article  CAS  PubMed  Google Scholar 

  166. Munoz F, Franco P, Ciammella P, Clerico M, Giudici M, Filippi AR, et al. Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat Oncol. 2007;2:15.

    Article  PubMed  PubMed Central  Google Scholar 

  167. Dundore PA, Cheville JC, Nascimento AG, Farrow GM, Bostwick DG. Carcinosarcoma of the prostate. Report of 21 cases. Cancer. 1995;76(6):1035–42.

    Article  CAS  PubMed  Google Scholar 

  168. Ordonez NG, Ayala AG, von Eschenbach AC, Mackay B, Hanssen G. Immunoperoxidase localization of prostatic acid phosphatase in prostatic carcinoma with sarcomatoid changes. Urology. 1982;19(2):210–4.

    Article  CAS  PubMed  Google Scholar 

  169. Nazeer T, Barada JH, Fisher HA, Ross JS. Prostatic carcinosarcoma: case report and review of literature. J Urol. 1991;146(5):1370–3.

    Article  CAS  PubMed  Google Scholar 

  170. Shannon RL, Ro JY, Grignon DJ, Ordóñez NG, Johnson DE, Mackay B, et al. Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer. 1992;69(11):2676–82.

    Article  CAS  PubMed  Google Scholar 

  171. Wick MR, Young RH, Malvesta R, Beebe DS, Hansen JJ, Dehner LP. Prostatic carcinosarcomas. Clinical, histologic, and immunohistochemical data on two cases, with a review of the literature. Am J Clin Pathol. 1989;92(2):131–9.

    Article  CAS  PubMed  Google Scholar 

  172. Ogawa K, Kim YC, Nakashima Y, Yamabe H, Takeda T, Hamashima Y. Expression of epithelial markers in sarcomatoid carcinoma: an immunohistochemical study. Histopathology. 1987;11(5):511–22.

    Article  CAS  PubMed  Google Scholar 

  173. Amin MB, Bostwick DG. Pigment in prostatic epithelium and adenocarcinoma: a potential source of diagnostic confusion with seminal vesicular epithelium. Mod Pathol. 1996;9(7):791–5.

    CAS  PubMed  Google Scholar 

  174. Shidham VB, Lindholm PF, Kajdacsy-Balla A, Basir Z, George V, Garcia FU. Prostate-specific antigen expression and lipochrome pigment granules in the differential diagnosis of prostatic adenocarcinoma versus seminal vesicle-ejaculatory duct epithelium. Arch Pathol Lab Med. 1999;123(11):1093–7.

    Article  CAS  PubMed  Google Scholar 

  175. Ormsby AH, Haskell R, Jones D, Goldblum JR. Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. Mod Pathol. 2000;13(1):46–51.

    Article  CAS  PubMed  Google Scholar 

  176. Varma M, Morgan M, O’Rourke D, Jasani B. Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle\ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens. Histopathology. 2004;44(4):405–6.

    Article  CAS  PubMed  Google Scholar 

  177. Bartman AE, Buisine MP, Aubert JP, Niehans GA, Toribara NW, Kim YS, et al. The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues. J Pathol. 1998;186(4):398–405.

    Article  CAS  PubMed  Google Scholar 

  178. Amin MB, Schultz DS, Zarbo RJ. Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med. 1994;118(3):260–4.

    CAS  PubMed  Google Scholar 

  179. McNeal JE, Reese JH, Redwine EA, Freiha FS, Stamey TA. Cribriform adenocarcinoma of the prostate. Cancer. 1986;58(8):1714–9.

    Article  CAS  PubMed  Google Scholar 

  180. Samaratunga H, Singh M. Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol. 1997;21(4):435–40.

    Article  CAS  PubMed  Google Scholar 

  181. Bostwick DG, Hossain D, Qian J, Neumann RM, Yang P, Young RH, et al. Phyllodes tumor of the prostate: long-term followup study of 23 cases. J Urol. 2004;172(3):894–9.

    Article  PubMed  Google Scholar 

  182. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 1996;20(4):419–26.

    Article  CAS  PubMed  Google Scholar 

  183. Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26(7):921–5.

    Article  PubMed  Google Scholar 

  184. Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004;28(2):239–43.

    Article  PubMed  Google Scholar 

  185. Armah HB, Parwani AV. Atypical adenomatous hyperplasia (adenosis) of the prostate: a case report with review of the literature. Diagn Pathol. 2008;3:34.

    Article  PubMed  PubMed Central  Google Scholar 

  186. Qian J, Bostwick DG. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract. 1995;191(9):860–7.

    Article  CAS  PubMed  Google Scholar 

  187. Cheng L, Bostwick DG. Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. Histopathology. 2010;56(5):627–31.

    Article  PubMed  Google Scholar 

  188. Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol. 1995;19(5):506–18.

    Article  CAS  PubMed  Google Scholar 

  189. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol. 2008;32(6):851–7.

    Article  PubMed  Google Scholar 

  190. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13(5):389–96.

    Article  CAS  PubMed  Google Scholar 

  191. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol. 1997;21(3):289–95.

    Article  CAS  PubMed  Google Scholar 

  192. Alexiev BA, LeVea CM. Nephrogenic adenoma of the urinary tract: a review. Int J Surg Pathol. 2012;20(2):123–31.

    Article  PubMed  Google Scholar 

  193. Allan CH, Epstein JI. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. Am J Surg Pathol. 2001;25(6):802–8.

    Article  CAS  PubMed  Google Scholar 

  194. Gupta A, Wang HL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR, et al. Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol. 2004;28(9):1224–9.

    Article  PubMed  Google Scholar 

  195. Skinnider BF, Oliva E, Young RH, Amin MB. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol. 2004;28(6):701–5.

    Article  PubMed  Google Scholar 

  196. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, et al. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol. 2009;33(7):1031–6.

    Article  PubMed  Google Scholar 

  197. Xiao GQ, Burstein DE, Miller LK, Unger PD. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med. 2006;130(6):805–10.

    Article  PubMed  Google Scholar 

  198. Rahemtullah A, Oliva E. Nephrogenic adenoma: an update on an innocuous but troublesome entity. Adv Anat Pathol. 2006;13(5):247–55.

    Article  PubMed  Google Scholar 

  199. Tong GX, Melamed J, Mansukhani M, Memeo L, Hernandez O, Deng FM, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol. 2006;19(3):356–63.

    Article  CAS  PubMed  Google Scholar 

  200. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol. 2008;32(9):1380–7.

    Article  PubMed  Google Scholar 

  201. Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy. Am J Surg Pathol. 2003;27(2):206–12.

    Article  PubMed  Google Scholar 

  202. Gaudin PB, Zelefsky MJ, Leibel SA, Fuks Z, Reuter VE. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol. 1999;23(9):1021–31.

    Article  CAS  PubMed  Google Scholar 

  203. Brawer MK, Nagle RB, Pitts W, Freiha F, Gamble SL. Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer. 1989;63(3):454–60.

    Article  CAS  PubMed  Google Scholar 

  204. Ljung G, Norberg M, Holmberg L, Busch C, Nilsson S. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. Prostate. 1997;31(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  205. Grob BM, Schellhammer PF, Brassil DN, Wright GL Jr. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology. 1994;44(4):525–9.

    Article  CAS  PubMed  Google Scholar 

  206. Mahan DE, Bruce AW, Manley PN, Franchi L. Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. J Urol. 1980;124(4):488–91.

    Article  CAS  PubMed  Google Scholar 

  207. Gikas PW, Del Buono EA, Epstein JI. Florid hyperplasia of mesonephric remnants involving prostate and periprostatic tissue. Possible confusion with adenocarcinoma. Am J Surg Pathol. 1993;17(5):454–60.

    Article  CAS  PubMed  Google Scholar 

  208. Bostwick DG, Qian J, Ma J, Muir TE. Mesonephric remnants of the prostate: incidence and histologic spectrum. Mod Pathol. 2003;16(7):630–5.

    Article  PubMed  Google Scholar 

  209. Gagucas RJ, Brown RW, Wheeler TM. Verumontanum mucosal gland hyperplasia. Am J Surg Pathol. 1995;19(1):30–6.

    Article  CAS  PubMed  Google Scholar 

  210. Gaudin PB, Wheeler TM, Epstein JI. Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol. 1995;104(6):620–6.

    Article  CAS  PubMed  Google Scholar 

  211. Gaudin PB, Reuter VE. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol. 1997;2:111–34.

    CAS  PubMed  Google Scholar 

  212. Muezzinoglu B, Erdamar S, Chakraborty S, Wheeler TM. Verumontanum mucosal gland hyperplasia is associated with atypical adenomatous hyperplasia of the prostate. Arch Pathol Lab Med. 2001;125(3):358–60.

    Article  CAS  PubMed  Google Scholar 

  213. Cina SJ, Silberman MA, Kahane H, Epstein JI. Diagnosis of Cowper’s glands on prostate needle biopsy. Am J Surg Pathol. 1997;21(5):550–5.

    Article  CAS  PubMed  Google Scholar 

  214. Saboorian MH, Huffman H, Ashfaq R, Ayala AG, Ro JY. Distinguishing Cowper’s glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies. Am J Surg Pathol. 1997;21(9):1069–74.

    Article  CAS  PubMed  Google Scholar 

  215. Frauenhoffer EE, Ro JY, el-Naggar AK, Ordonez NG, Ayala AG. Clear cell cribriform hyperplasia of the prostate. Immunohistochemical and DNA flow cytometric study. Am J Clin Pathol. 1991;95(4):446–53.

    Article  CAS  PubMed  Google Scholar 

  216. Ayala AG, Srigley JR, Ro JY, Abdul-Karim FW, Johnson DE. Clear cell cribriform hyperplasia of prostate. Report of 10 cases. Am J Surg Pathol. 1986;10(10):665–71.

    Article  CAS  PubMed  Google Scholar 

  217. Presti B, Weidner N. Granulomatous prostatitis and poorly differentiated prostate carcinoma. Their distinction with the use of immunohistochemical methods. Am J Clin Pathol. 1991;95(3):330–4.

    Article  CAS  PubMed  Google Scholar 

  218. Sebo TJ, Bostwick DG, Farrow GM, Eble JN. Prostatic xanthoma: a mimic of prostatic adenocarcinoma. Hum Pathol. 1994;25(4):386–9.

    Article  CAS  PubMed  Google Scholar 

  219. Chuang AY, Epstein JI. Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol. 2007;31(8):1225–30.

    Article  PubMed  Google Scholar 

  220. Luque RJ, Lopez-Beltran A, Perez-Seoane C, Suzigan S. Sclerosing adenosis of the prostate. Histologic features in needle biopsy specimens. Arch Pathol Lab Med. 2003;127(1):e14–6.

    Article  PubMed  Google Scholar 

  221. Jones EC, Clement PB, Young RH. Sclerosing adenosis of the prostate gland. A clinicopathological and immunohistochemical study of 11 cases. Am J Surg Pathol. 1991;15(12):1171–80.

    Article  CAS  PubMed  Google Scholar 

  222. Meister P. Sclerosing adenosis of the prostate. Carcinoma simulation [in German]. Pathologe. 1996;17(2):157–62.

    Article  CAS  PubMed  Google Scholar 

  223. Ronnett BM, Epstein JI. A case showing sclerosing adenosis and an unusual form of basal cell hyperplasia of the prostate. Am J Surg Pathol. 1989;13(10):866–72.

    Article  CAS  PubMed  Google Scholar 

  224. Ostrowski ML, Wheeler TM. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994;18(4):412–20.

    Article  CAS  PubMed  Google Scholar 

  225. Howarth SM, Griffiths DF, Varma M. Paraganglion of the prostate gland: an uncommon mimic of prostate cancer in needle biopsies. Histopathology. 2005;47(1):114–5.

    Article  CAS  PubMed  Google Scholar 

  226. Kawabata K. Paraganglion of the prostate in a needle biopsy: a potential diagnostic pitfall. Arch Pathol Lab Med. 1997;121(5):515–6.

    CAS  PubMed  Google Scholar 

  227. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6):747–54.

    Article  PubMed  Google Scholar 

  228. Simic T, Mimic-Oka J, Ille K, Dragicevic D, Savic-Radojevic A. Glutathione S-transferase isoenzyme profile in non-tumor and tumor human kidney tissue. World J Urol. 2003;20(6):385–91.

    Article  CAS  PubMed  Google Scholar 

  229. Grignon DJ, Abdel-Malak M, Mertens WC, Sakr WA, Shepherd RR. Glutathione S-transferase expression in renal cell carcinoma: a new marker of differentiation. Mod Pathol. 1994;7(2):186–9.

    CAS  PubMed  Google Scholar 

  230. May EE, Perentes E. Anti-Leu 7 immunoreactivity with human tumours: its value in the diagnosis of prostatic adenocarcinoma. Histopathology. 1987;11(3):295–304.

    Article  CAS  PubMed  Google Scholar 

  231. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13(11):1186–91.

    Article  CAS  PubMed  Google Scholar 

  232. Tawfic S, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol. 2003;34(5):450–6.

    Article  PubMed  Google Scholar 

  233. Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22(9):1218–27.

    Article  CAS  PubMed  Google Scholar 

  234. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21(2):192–200.

    Article  CAS  PubMed  Google Scholar 

  235. Gill R, O'Donnell RJ, Horvai A. Utility of immunohistochemistry for endothelial markers in distinguishing epithelioid hemangioendothelioma from carcinoma metastatic to bone. Arch Pathol Lab Med. 2009;133(6):967–72.

    Article  CAS  PubMed  Google Scholar 

  236. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25(8):1061–6.

    Article  CAS  PubMed  Google Scholar 

  237. Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol. 2001;116(1):115–21.

    Article  CAS  PubMed  Google Scholar 

  238. Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000;113(3):383–8.

    Article  CAS  PubMed  Google Scholar 

  239. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33(11):1136–40.

    Article  PubMed  Google Scholar 

  240. Mulders TM, Bruning PF, Bonfrer JM. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. Eur J Surg Oncol. 1990;16(1):37–41.

    CAS  PubMed  Google Scholar 

  241. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673–80.

    Article  PubMed  Google Scholar 

  242. Esheba GE, Longacre TA, Atkins KA, Higgins JP. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33(3):347–53.

    Article  PubMed  Google Scholar 

  243. Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138(1):57–64.

    Article  PubMed  Google Scholar 

  244. Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, Epstein JI. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36(10):1472–6.

    Article  PubMed  PubMed Central  Google Scholar 

  245. Zhao L, Antic T, Witten D, Paner GP, Taxy JB, Husain A, et al. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol. 2013;37(12):1876–81.

    Article  PubMed  Google Scholar 

  246. Gruver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136(11):1339–46.

    Article  PubMed  Google Scholar 

  247. Shahab A, Liu H, Lin F. Uroplakin II is a useful immunomarker for identification of urothelial carcinomas [USCAP abstract 1072]. Mod Pathol. 2014;27(S2):260A.

    Google Scholar 

  248. Soslow RA, Rouse RV, Hendrickson MR, Silva EG, Longacre TA. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15(3):257–65.

    Article  CAS  PubMed  Google Scholar 

  249. Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, et al. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int. 2008;58(11):687–94.

    Article  CAS  PubMed  Google Scholar 

  250. Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer. 2000;88(2):407–15.

    Article  CAS  PubMed  Google Scholar 

  251. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol. 1999;23(10):1173–83.

    Article  CAS  PubMed  Google Scholar 

  252. Herawi M, Epstein JI. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2006;30(6):694–704.

    Article  PubMed  Google Scholar 

  253. Herawi M, Montgomery EA, Epstein JI. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: a clinicopathologic study of 8 cases. Am J Surg Pathol. 2006;30(11):1389–95.

    Article  PubMed  Google Scholar 

  254. Herawi M, Epstein JI. Solitary fibrous tumor on needle biopsy and transurethral resection of the prostate: a clinicopathologic study of 13 cases. Am J Surg Pathol. 2007;31(6):870–6.

    Article  PubMed  Google Scholar 

  255. Pins MR, Campbell SC, Laskin WB, Steinbronn K, Dalton DP. Solitary fibrous tumor of the prostate a report of 2 cases and review of the literature. Arch Pathol Lab Med. 2001;125(2):274–7.

    Article  CAS  PubMed  Google Scholar 

  256. Mentzel T, Bainbridge TC, Katenkamp D. Solitary fibrous tumour: clinicopathological, immunohistochemical, and ultrastructural analysis of 12 cases arising in soft tissues, nasal cavity and nasopharynx, urinary bladder and prostate. Virchows Arch. 1997;430(6):445–53.

    Article  CAS  PubMed  Google Scholar 

  257. Wang X, Jones TD, Zhang S, Eble JN, Bostwick DG, Qian J, et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol. 2007;20(2):175–82.

    Article  CAS  PubMed  Google Scholar 

  258. Hansel DE, Herawi M, Montgomery E, Epstein JI. Spindle cell lesions of the adult prostate. Mod Pathol. 2007;20(1):148–58.

    Article  CAS  PubMed  Google Scholar 

  259. Cohen MB. Atypical prostatic stromal lesions. Adv Anat Pathol. 1998;5(6):359–66.

    Article  CAS  PubMed  Google Scholar 

  260. Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG. Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med. 2008;132(11):1729–33.

    Article  PubMed  Google Scholar 

  261. Bierhoff E, Vogel J, Benz M, Giefer T, Wernert N, Pfeifer U. Stromal nodules in benign prostatic hyperplasia. Eur Urol. 1996;29(3):345–54.

    Article  CAS  PubMed  Google Scholar 

  262. Bierhoff E, Walljasper U, Hofmann D, Vogel J, Wernert N, Pfeifer U. Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate. 1997;31(4):234–40.

    Article  CAS  PubMed  Google Scholar 

  263. Gupta R, Singh S, Khurana N. Leiomyoma of the prostate--a rare mesenchymal tumor: a case report. Indian J Pathol Microbiol. 2007;50(2):403–5.

    PubMed  Google Scholar 

  264. Srinivasan G, Campbell E, Bashirelahi N. Androgen, estrogen, and progesterone receptors in normal and aging prostates. Microsc Res Tech. 1995;30(4):293–304.

    Article  CAS  PubMed  Google Scholar 

  265. Montgomery EA, Shuster DD, Burkart AL, Esteban JM, Sgrignoli A, Elwood L, et al. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol. 2006;30(12):1502–12.

    Article  PubMed  Google Scholar 

  266. Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1998;22(2):148–62.

    Article  CAS  PubMed  Google Scholar 

  267. Young RH, Scully RE. Pseudosarcomatous lesions of the urinary bladder, prostate gland, and urethra. A report of three cases and review of the literature. Arch Pathol Lab Med. 1987;111(4):354–8.

    CAS  PubMed  Google Scholar 

  268. Mobbs BG, Liu Y. Immunohistochemical localization of progesterone receptor in benign and malignant human prostate. Prostate. 1990;16(3):245–51.

    Article  CAS  PubMed  Google Scholar 

  269. Morikawa T, Goto A, Tomita K, Tsurumaki Y, Ota S, Kitamura T, et al. Recurrent prostatic stromal sarcoma with massive high-grade prostatic intraepithelial neoplasia. J Clin Pathol. 2007;60(3):330–2.

    Article  PubMed  PubMed Central  Google Scholar 

  270. Dotan ZA, Tal R, Golijanin D, Snyder ME, Antonescu C, Brennan MF, et al. Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol. 2006;176(5):2033–8.

    Article  PubMed  Google Scholar 

  271. Cheville JC, Dundore PA, Nascimento AG, Meneses M, Kleer E, Farrow GM, et al. Leiomyosarcoma of the prostate. Report of 23 cases. Cancer. 1995;76(8):1422–7.

    Article  CAS  PubMed  Google Scholar 

  272. Janet NL, May AW, Akins RS. Sarcoma of the prostate: a single institutional review. Am J Clin Oncol. 2009;32(1):27–9.

    Article  PubMed  Google Scholar 

  273. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001;166(2):521–5.

    Article  CAS  PubMed  Google Scholar 

  274. Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12(4):338–41.

    Article  CAS  PubMed  Google Scholar 

  275. Fisher C, Goldblum JR, Epstein JI, Montgomery E. Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol. 2001;25(9):1143–9.

    Article  CAS  PubMed  Google Scholar 

  276. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001;14(5):506–14.

    Article  CAS  PubMed  Google Scholar 

  277. Kuhnen C, Herter P, Muller O, Muehlberger T, Krause L, Homann H, et al. Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol. 2000;13(9):1005–13.

    Article  CAS  PubMed  Google Scholar 

  278. Waring PM, Newland RC. Prostatic embryonal rhabdomyosarcoma in adults. A clinicopathologic review. Cancer. 1992;69(3):755–62.

    Article  CAS  PubMed  Google Scholar 

  279. Nabi G, Dinda AK, Dogra PN. Primary embryonal rhabdomyosarcoma of prostate in adults: diagnosis and management. Int Urol Nephrol. 2002;34(4):531–4.

    Article  CAS  PubMed  Google Scholar 

  280. Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e6–e19.

    Article  PubMed  Google Scholar 

  281. Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, et al. Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol. 2014;38(8):1017–22.

    Article  PubMed  Google Scholar 

  282. Humphrey PA. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol. 2018;31(S1):S64–70.

    Article  PubMed  Google Scholar 

  283. Zhou M. High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol. 2018;31(S1):S71–9.

    Article  PubMed  Google Scholar 

  284. Sailer V, Stephan C, Wernert N, Perner S, Jung K, Dietel M, et al. Comparison of p40 (ΔNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? Histopathology. 2013;63(1):50–6.

    Article  PubMed  Google Scholar 

  285. Uchida K, Ross H, Lotan T, Pignon JC, Signoretti S, Epstein JI, et al. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Hum Pathol. 2015;46(3):384–9.

    Article  CAS  PubMed  Google Scholar 

  286. Brustmann H. p40 as a basal cell marker in the diagnosis of prostate glandular proliferations: a comparative immunohistochemical study with 34betaE12. Pathol Res Int. 2015;2015:897927.

    Article  Google Scholar 

  287. Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, et al. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate. 2018;78(12):896–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  288. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756–67.

    Article  PubMed  PubMed Central  Google Scholar 

  289. Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1):S122–32.

    Article  PubMed  Google Scholar 

  290. Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, et al. FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene. 2017;36(28):4072–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  291. Roy M, Buehler DG, Zhang R, Schwalbe ML, Baus RM, Salamat MS, et al. Expression of insulinoma-associated protein 1 (INSM1) and orthopedia homeobox (OTP) in tumors with neuroendocrine differentiation at rare sites. Endocr Pathol. 2019;30(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  292. Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification. Endocr Pathol. 2016;27(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  293. Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks J, et al. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015;21(24):5619–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  294. Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11(4):213–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  295. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011;24(6):820–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  296. Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol. 2019;32:100–9.

    Article  CAS  PubMed  Google Scholar 

  297. Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, et al. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol. 2018;79:151–9.

    Article  CAS  PubMed  Google Scholar 

  298. Kim IE, Amin A, Wang LJ, Cheng L, Perrino CM. Insulinoma-associated protein 1 (INSM1) expression in small cell neuroendocrine carcinoma of the urinary tract. Appl Immunohistochem Mol Morphol. 2020;28(9):687–93.

    Article  CAS  PubMed  Google Scholar 

  299. Zhang G, McDaniel AS, Mehra R, McKenney JK. Nephrogenic adenoma does not express NKX3.1. Histopathology. 2017;71(4):669–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Haiyan Liu & Fan Lin

  2. Department of Pathology and Lab Medicine, Mayo Clinic Florida, Jacksonville, FL, USA

    Qihui “Jim” Zhai

Authors
  1. Haiyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qihui “Jim” Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haiyan Liu .

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Fan Lin

  2. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Jeffrey W. Prichard

  3. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Haiyan Liu

  4. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Myra L. Wilkerson

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Geisinger Clinic

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Liu, H., Lin, F., Zhai, Q.“. (2022). Prostate Gland. In: Lin, F., Prichard, J.W., Liu, H., Wilkerson, M.L. (eds) Handbook of Practical Immunohistochemistry. Springer, Cham. https://doi.org/10.1007/978-3-030-83328-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-83328-2_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-83327-5

  • Online ISBN: 978-3-030-83328-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation